The first attempt at using PSMA as a tumor marker in order to obtain images was done in the form of an 111In-labeled monoclonal antibody (mAb)—[111In]In-capromab pendetide or ProstaScint®—to be used in SPECT tomography. Here, FOLH1 is linked to neoplasm.